Drug Type Antibody drug conjugate (ADC) |
Synonyms + [2] |
Target |
Action inhibitors |
Mechanism CLDN6 inhibitors(Claudin 6 inhibitors), Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC40H59NO11 |
InChIKeyUFNVPOGXISZXJD-JBQZKEIOSA-N |
CAS Registry253128-41-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Testicular Neoplasms | Preclinical | China | 28 Apr 2025 | |
Ovarian Cancer | Preclinical | China | 01 Dec 2024 |